Therapy News and Research

RSS

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Baxter International Inc. today announced completion of CE marking in Europe for the VIVIA hemodialysis system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.

From Baxter International Inc. 20 Dec 2013

Coupling meditation-like practices with drug and behavior therapies more helpful in tackling addiction

Using a computational model of addiction, a literature review and an in silico experiment, theoretical computer scientist Yariv Levy and colleagues suggest in a new paper this week that rehabilitation strategies coupling meditation-like practices with drug and behavior therapies are more helpful than drug-plus-talk therapy alone when helping people overcome addiction.

20 Dec 2013

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

IQWiG reassesses vemurafenib for treatment of advanced melanoma

Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment of adults with a certain type of advanced melanoma.

20 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

On Dec. 18, Keck Medicine of USC became the world's first medical center to implant a responsive brain device newly approved by the Food and Drug Administration to treat epilepsy, with potential to help millions of people worldwide.

20 Dec 2013

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study.

20 Dec 2013

Study: Standard treatment approaches yield modest to large improvement in TMD patients

empromandibular pain disorders (TMDs) are characterized by a dysfunction of the TMD joint and cause orofacial pain, masticatory dysfunction or both.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

Researchers receive 3 Patient-Centered Outcomes Research Institute awards from PCORI

Research teams at Group Health Research Institute have been approved for funding awards by the Patient-Centered Outcomes Research Institute (PCORI) to study opioid therapy and asthma-and to help expand a health data network that will be part of PCORnet: the National Patient-Centered National Clinical Research Network.

20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

COPD undertreatment widespread

A study has shown that undertreatment of chronic obstructive pulmonary disease is highly prevalent.

19 Dec 2013

Study investigates about emotions that affects patients with Parkinson's disease

Is it the disease itself or the treatment that impairs the perception of emotions? A study conducted with the collaboration of the International School for Advanced Studies (SISSA) of Trieste investigates the origins of the difficulty recognizing certain emotions that affects patients with Parkinson's disease.

19 Dec 2013

Computer-controlled, rotating table could deliver high doses of radiotherapy to tumors, spare vulnerable organs

Swivelling patients around on a computer-controlled, rotating table could deliver high doses of radiotherapy to tumours more quickly than current methods, while sparing vulnerable organs such as the heart, brain, eyes and bowel.

19 Dec 2013

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern Medical Center has launched the local arm of a national, multicenter study aimed at finding more effective treatments for alcoholic hepatitis, a disease of the liver that often leads to cirrhosis and death in severe cases.

19 Dec 2013

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

Therapy News and Research

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Coupling meditation-like practices with drug and behavior therapies more helpful in tackling addiction

New antibody could boost strength, muscle mass in patients with cancer and other diseases

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

IQWiG reassesses vemurafenib for treatment of advanced melanoma

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

USC's Keck Medicine becomes world's first center to implant responsive brain device to treat epilepsy

People with diabetes at risk of developing diabetic macular edema during their lifetime

Study: Standard treatment approaches yield modest to large improvement in TMD patients

New research assesses nanomedicine-based approaches for treating cancer

Researchers develop oral vaccine against Helicobacter pylori

Researchers receive 3 Patient-Centered Outcomes Research Institute awards from PCORI

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

COPD undertreatment widespread

Study investigates about emotions that affects patients with Parkinson's disease

Computer-controlled, rotating table could deliver high doses of radiotherapy to tumors, spare vulnerable organs

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News